Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A

SSZSE:301096
38.64
CNY
+0.86
(+2.28%)
-1.65EPS
5.38BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A carries a market capitalization of 5.38B, placing it among publicly traded companies globally. Its enterprise value stands at 5.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.38B
Enterprise Value5.99B

Important Dates

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A has 109.23M shares outstanding.

Shares Outstanding109.23M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 8.65, and the price-to-book ratio stands at 2.22.

PS Ratio8.65
PB Ratio2.22
P/TBV Ratio2.30

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 9.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.99B versus a market cap of 5.38B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.69

Financial Position

As of September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.98, indicating elevated leverage, while an interest coverage ratio of -7.91 demonstrates limited ability to service its debt obligations.

Current Ratio1.83
Quick Ratio0.39
Debt / Equity38.98
Debt / EBITDA-5.32
Interest Coverage-7.91

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A posted a negative return on equity (ROE) of -7.11, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.71, reflecting losses generated across the asset base. The company generates approximately 437,639.54 in revenue per employee across its workforce of 1,412.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.08 indicates how many times Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-7.11
Return on Assets (ROA)-4.71
Revenue Per Employee437,639.54
Employee Count1,412.00
Inventory Turnover2.08

Taxes

CNY

Over the twelve months ended September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A recorded an income tax benefit of -4.36M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -183.49M and -178.17M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-4.36M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A's stock has declined approximately 27.18% over the past 52 weeks. The 50-day moving average sits at 44.58, while the 200-day moving average is 50.30.

52-Week Price Change-27.18%
50-Day Moving Average44.58
200-Day Moving Average50.30

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A generated 617.95M in revenue and converted that into -178.17M in net income, yielding earnings per share of -1.65. EBITDA reached -177.66M, while operating income came in at -114.14M.

Revenue617.95M
Gross Profit203.19M
Operating Income-114.14M
Pretax Income-183.49M
Net Income-178.17M
EBITDA-177.66M
EBIT-177.66M
Earnings Per Share (EPS)-1.65

Balance Sheet

CNY

As of September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A holds 343.92M in cash and equivalents against 946.00M in total debt, resulting in a net debt position of 465.76M. Total book value stands at 2.43B, with working capital of 736.41M providing operational flexibility.

Cash & Cash Equivalents343.92M
Total Debt946.00M
Net Debt465.76M
Equity (Book Value)2.43B
Book Value Per Share22.21
Working Capital736.41M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-85.85M

Margins

Over the twelve months ended September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A posted a gross margin of 32.88, reflecting its pricing power and cost economics. The operating margin of -18.47 and net profit margin of -28.83 provide insight into operational efficiency.

Gross Margin32.88
Operating Margin-18.47
Pretax Margin-29.69
Profit Margin-28.83
EBITDA Margin-28.75

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A paid dividends of 0.20 per share. The dividend payout ratio of -11.75 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A shareholders.

Dividend Per Share0.20
Payout Ratio-11.75
Shareholder Yield1.99

Scores

As of September 30, 2026, Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A has an Altman Z-Score of 2.95, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.95